Legal & General Group
CARM

Legal & General Group’s Carisma Therapeutics CARM Stock Holding History

Legal & General Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,156
Closed -$4.89K – 3431
2024
Q1 		$4.89K Hold
2,156
– – ﹤0.01% 3299
2023
Q4 		$6.32K Hold
2,156
– – ﹤0.01% 3301
2023
Q3 		$9.13K Sell
2,156
-411
-16% -$2.6K ﹤0.01% 3285
2023
Q2 		$22.5K Buy
+2,567
New +$14K ﹤0.01% 3072
2022
Q2 		– Sell
-1,295
Closed -$15K – 3541
2022
Q1 		$15K Buy
1,295
+68
+6% +$950 ﹤0.01% 3296
2021
Q4 		$20K Hold
1,227
– – ﹤0.01% 3276
2021
Q3 		$19K Buy
1,227
+135
+12% +$6.48K ﹤0.01% 3290
2021
Q2 		$101K Buy
+1,092
New +$69.6K ﹤0.01% 2728

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legal & General Group's CARM Position: Q2 2024 in Review

Legal & General Group sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 2,156 shares — an estimated $4.89K sold.

Legal & General Group first reported a position in CARM in Q2 2021 and held it in 8 quarters. The position peaked at $101K in Q2 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Legal & General Group reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 2,156 Carisma Therapeutics shares in Q2 2024, an estimated $4.89K.
  • Legal & General Group first reported a position in Carisma Therapeutics in Q2 2021 and held it in 8 quarters.
  • Legal & General Group's Carisma Therapeutics position peaked at $101K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.